Bevacizumab [Zirabev]

[MSHL] Bevacizumab biosimilar Concentrate For Solution For Infusion 100 mg/4 mL, 400 mg/16 mL

1. For cancer treatment.

[MSHL] Bevacizumab Concentrate For Solution For Infusion 100 mg/4 mL, 400 mg/16 mL

1. Atezolizumab in combination with bevacizumab (non-subsidised brand) and platinum-doublet chemotherapy, for the treatment of patients with metastatic non-squamous non-small cell lung cancer (NSCLC) who had not received prior chemotherapy. Patients must not have received prior treatment with a PD-1/PD-L1 inhibitor for metastatic NSCLC.

2. Atezolizumab in combination with bevacizumab (non-subsidised brand) for treating advanced unresectable hepatocellular carcinoma in patients who have not received prior systemic therapy, and who have adequate liver function as assessed by the Child-Pugh scoring system.

[MSHL] Bevacizumab Concentrate For Solution For Infusion 100 mg/4 mL, 400 mg/16 mL

1. Olaparib in combination with bevacizumab (non-subsidised brand) as maintenance treatment of patients with advanced homologous recombination deficiency (HRD) positive high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy in combination with bevacizumab.
   Treatment with olaparib should be continued until disease progression or unacceptable toxicity or for a maximum of 24 months.

View legend

01/08/2025 Bevacizumab biosimilar for treating different types of cancer

The Ministry of Health’s Drug Advisory Committee has recommended:

• Bevacizumab biosimilar (Mvasi) 100 mg/4 mL and 400 mg/16 mL concentrate for solution for infusion in line with its registered indications or local clinical protocols for treating:

  • Persistent, recurrent or metastatic cervical cancer when used with platinum-based chemotherapy plus paclitaxel;

  • Metastatic colorectal cancer when used with fluoropyrimidine-based chemotherapy;

  • Malignant glioma (WHO Grade III and IV) after relapse or disease progression following prior therapy;

  • Previously untreated, unresectable, locally advanced, recurrent or metastatic non-squamous non-small-cell lung cancer when used with carboplatin and paclitaxel;

  • Previously untreated, advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer in patients who have suboptimally debulked Stage III disease with more than 1 cm of residual disease or Stage III unresectable or Stage IV disease;

  • Recurrent, platinum-sensitive, epithelial ovarian, fallopian tube, or primary peritoneal cancer when used with carboplatin and gemcitabine or paclitaxel;

  • Recurrent, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer when used with paclitaxel, topotecan or pegylated liposomal doxorubicin; and

  • Advanced homologous recombination deficiency (HRD) positive high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer as maintenance treatment in combination with olaparib in patients who are in complete or partial response to first-line platinum-based chemotherapy in combination with bevacizumab biosimilar.

Subsidy status

[R] Bevacizumab biosimilar (Mvasi) 100 mg/4 mL and 400 mg/16 mL concentrate for solution for infusion are recommended for inclusion on the MOH Standard Drug List (SDL) for the abovementioned indications with effect from 1 April 2022.

[NR] SDL subsidy does not apply to any formulations or strengths of bevacizumab reference biologic (Avastin) or other brands of bevacizumab biosimilars.

Clinical indications, subsidy class and MediShield Life claim limits are provided in the Annex.

View legend